Shantou S.E.Z. Baojie Industry Co., Ltd. – FDA Warning Letter, Aug 30, 2024

The FDA issued a Warning Letter to Shantou S.E.Z. Baojie Industry Co., Ltd. following an inspection from August 26-30, 2024, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Failure to test components:** The firm did not adequately test incoming components for identity, purity, strength, and quality, relying on supplier COAs without validation, and failed to test high-risk components for contamination despite prior commitments. 2. **Inadequate production and process controls:** The firm lacked established procedures for its (b)(4) system, used as a component and for cleaning, failing to ensure its design, maintenance, monitoring, and appropriate testing for suitability and microbiological control. 3. **Insufficient stability testing:** The firm lacked adequate stability data to support labeled expiry dates, with stability testing procedures limited to organoleptic assessment, omitting chemical and microbial analysis. 4. **Quality control unit failures:** The quality unit failed to provide adequate oversight, not ensuring CGMP compliance or adherence to specifications for identity, strength, quality, and purity.

The FDA deemed the firm's responses to the Form FDA 483 inadequate, citing a lack of detail on corrective actions, impact assessments on U.S. market products, and scientific rationale. The FDA recommended engaging a qualified CGMP consultant to evaluate operations